Why the study?
POAF occurs in 30% to 60% of patients undergoing cardiac surgery and impairs outcomes, prompting interest in BTX epicardial injection to impair cholinergic signaling and prevent POAF.
Does botulinum toxin type A epicardial fat injection prevent postoperative atrial fibrillation in patients undergoing cardiac surgery?
Does botulinum toxin type A epicardial fat injection prevent postoperative atrial fibrillation in patients undergoing cardiac surgery?
Epicardial fat injection of botulinum toxin type A does not significantly reduce the incidence of postoperative atrial fibrillation compared to placebo in patients undergoing cardiac surgery.
Answers are grounded in this paper and cite their sources.
No benefit for POAF prevention after cardiac surgery; confirms lack of efficacy and redirects research to alternative strategies.
Background: Postoperative atrial fibrillation (POAF) is prevalent in about 30% to 60% of patients undergoing cardiac surgery, leading to worse outcomes. Botulinum toxin type A (BTX) epicardial injection has been proposed to prevent POAF by impairing cholinergic signaling. Methods: A systematic review and meta-analysis synthesized randomized controlled trials, which were retrieved by searching PubMed, EMBASE, Web of Science, SCOPUS, and Cochrane through November 23, 2022. RevMan version 5.4 was used to pool dichotomous outcomes using risk ratio (RR) and continuous outcomes using mean differences (MD) presented with the corresponding confidence interval (CI). Conclusion: There was no difference between the epicardial fat injection of BTX versus placebo for preventing POAF.
No takes yet. Share an insight, caveat, or question.
Abuelazm et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: